Antibe Therapeutics Inc.

ATBPF · OTC
Analyze with AI
3/31/2023
3/31/2022
3/31/2021
3/31/2020
Operating Activities
Net Income-$19,475-$25,060-$24,734-$19,342
Dep. & Amort.$0$99$478$572
Deferred Tax$0$0$452$1,600
Stock-Based Comp.$2,808$5,521$3,989$3,376
Change in WC$28$2,502$19,659$1,691
Other Non-Cash$334$18$52$168
Operating Cash Flow-$16,305-$16,920-$105-$11,935
Investing Activities
PP&E Inv.-$9-$9$0-$2
Net Acquisitions$0-$236$0$0
Inv. Purchases-$48,436-$19,975$0$0
Inv. Sales/Matur.$36,299$20$0$100
Other Inv. Act.$319-$20-$264-$560
Investing Cash Flow-$11,827-$20,220-$264$98
Financing Activities
Debt Repay.-$79-$152-$2,411-$190
Stock Issued$0$128$69,115$8,050
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$159$126-$544$4,143
Financing Cash Flow$80-$26$66,160$12,003
Forex Effect$0$0$0$23
Net Chg. in Cash-$28,052-$37,166$65,791$189
Supplemental Information
Beg. Cash$34,807$71,973$6,182$5,993
End Cash$6,755$34,807$71,973$6,182
Free Cash Flow-$16,314-$16,929-$105-$11,937